iBio Inc (IBIO)
1.76
+0.04
(+2.33%)
USD |
NYAM |
Apr 26, 16:00
1.76
0.00 (0.00%)
After-Hours: 20:00
iBio Cash from Operations (TTM): -18.89M for Dec. 31, 2023
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
Date | Value |
---|---|
December 31, 2023 | -18.89M |
September 30, 2023 | -21.82M |
June 30, 2023 | -30.44M |
March 31, 2023 | -36.97M |
December 31, 2022 | -39.04M |
September 30, 2022 | -42.09M |
June 30, 2022 | -37.48M |
March 31, 2022 | -33.20M |
December 31, 2021 | -34.61M |
September 30, 2021 | -32.34M |
June 30, 2021 | -30.06M |
March 31, 2021 | -26.70M |
December 31, 2020 | -23.14M |
September 30, 2020 | -18.13M |
June 30, 2020 | -13.34M |
March 31, 2020 | -13.87M |
December 31, 2019 | -14.22M |
September 30, 2019 | -15.48M |
June 30, 2019 | -13.98M |
March 31, 2019 | -12.96M |
December 31, 2018 | -12.32M |
September 30, 2018 | -11.24M |
June 30, 2018 | -13.48M |
March 31, 2018 | -13.87M |
December 31, 2017 | -13.93M |
Date | Value |
---|---|
September 30, 2017 | -13.91M |
June 30, 2017 | -13.16M |
March 31, 2017 | -12.22M |
December 31, 2016 | -11.10M |
September 30, 2016 | -9.198M |
June 30, 2016 | -8.072M |
March 31, 2016 | -6.457M |
December 31, 2015 | -5.346M |
September 30, 2015 | -5.302M |
June 30, 2015 | -4.725M |
March 31, 2015 | -4.202M |
December 31, 2014 | -4.104M |
September 30, 2014 | -3.775M |
June 30, 2014 | -4.116M |
March 31, 2014 | -4.341M |
December 31, 2013 | -4.36M |
September 30, 2013 | -4.47M |
June 30, 2013 | -4.849M |
March 31, 2013 | -4.980M |
December 31, 2012 | -6.692M |
September 30, 2012 | -6.072M |
June 30, 2012 | -6.01M |
March 31, 2012 | -6.068M |
December 31, 2011 | -5.119M |
September 30, 2011 | -6.040M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (TTM) Range, Past 5 Years
-42.09M
Minimum
Sep 2022
-13.34M
Maximum
Jun 2020
-26.10M
Average
-26.70M
Median
Mar 2021
Cash from Operations (TTM) Benchmarks
Lixte Biotechnology Holdings Inc | -4.293M |
PAVmed Inc | -52.04M |
Avalo Therapeutics Inc | -30.68M |
Imunon Inc | -19.02M |
Ocugen Inc | -62.05M |